In conclusion, we have developed an LC-MS/MS method for measuring Sal-T in men, which could be used as a surrogate marker for biologically available testosterone. The availability of a Sal-T assay that is reliable at low concentrations will facilitate improved clinical utility and decision-making for the laboratory assessment of androgen status in men.
Regarding the Overestimation of Serum Free Light Chains
To the Editor:
I read with interest 2 recent Letters to the Editor regarding the accuracy of serum free light chain (3 ) . We noticed that 3 of the 10 diluted serum samples showed a concentration that was increased 2-to 4-fold above that of the undiluted baseline value (4 ) . In another study, 10 of 10 serum samples showed recoveries of 175% to 381% after multiple dilutions, compared with the lowest dilution (5 ). The reagent manufacturer (Binding Site) has acknowledged variation in values at different dilutions and has indicated that the concentration of the baseline value should be reported when diluted values are Ͻ4-fold different.
Letters to the Editor
If the accuracy of the nephelometric assay is being questioned, then that of the ELISA should also be questioned. de Kat Angelino et al. compared nephelometry and ELISA results to those for serum protein electrophoresis (SPE) (1 ) . SPE densitometry produced monoclonal FLC concentrations between 2.3 g/L and 3.3 g/L for 4 samples, but these concentrations should be considered only estimates, because the monoclonal proteins migrated near the ␤ region or in the ␥ region, with a polyclonal background making exact quantification difficult. Nevertheless, the SPE concentrations were far less than the values of 22.4 -34.1 g/L obtained with the nephelometric FLC assay and were closer to the values of 1. (6 ) . Unfortunately, neither ELISA study compared parallelism between the calibrator and patient sera-one requirement for accuracy.
Finally, it is unlikely that extra sensitivity in the face of quantitative inaccuracy is advantageous, as Mead and Carr-Smith stated in their letter (2 ) . Clearly, a highly sensitive but nonlinear and inaccurate method may produce misleading results when used to monitor patients over time.
I conclude that the nephelometric assay is quantitatively inaccurate, but whether ELISA assays are more accurate remains unclear. ELISA methods for serum FLCs may prove superior to nephelometric methods and become the method of choice, but such a conclusion needs to be proved. If it is, ELISA methods need to be made generally available. Until that time, the nephelometric method should be used to help identify monoclonal FLCs, but because of its inaccuracy, it should otherwise be restricted to monitoring patients only when other methods, such as SPE, cannot be used (i.e., nonsecretory myeloma or FLC disease only). 
Role of Sponsor:
The funding organizations played a direct role in design and choice of enrolled patients.
To the Editor:
The Siemens cystatin C immunoassay has been widely used in clinical research, particularly in the US. In recent years, however, the results obtained with the method appear to have changed.
The glomerular filtration rate (GFR) is generally accepted as the best overall indicator of kidney function and is an important measure for assessing kidney disease. Several studies have shown cystatin C to be superior to creatinine for estimation of the GFR (1 ), which is usually expressed as the relative GFR [in units of mL ⅐ min
]. This practice has led to the development of formulas to convert cystatin C measurements in milligrams per liter to a calculated GFR in these units, without the need for demographic coefficients (2, 3 ) . The formulas were developed from studies that compared cystatin C concentrations with measured GFRs by using such exogenous markers as iohexol, diethylenetriamine pentaacetic acid or 51 Cr-EDTA clearance (4 ).
We were concerned that the calibration of the Siemens cystatin C method had changed during the last 5 years, because we noted that thecystatinCconcentrationsofparticipants in a longitudinal cohort improved substantially over time. The study investigators considered these results implausible because the GFR is known to decrease with age. The aim of the present study was to determine whether the Siemens cystatin C method has changed its calibration during the last 5 years and, if so, to quantify the magnitude of the change.
We used our laboratory's current routine method from Gentian as a comparative method. To ensure that the comparative method had been stable, we verified that each lot of the Gentian reagent produced results within 3% of the originally assigned values for 10 patient serum pools prepared in 2005 and stored at Ϫ70°C. Freshly collected and lithium heparin-treated samples obtained from routine cystatin C requests were then used to compare the 2 cystatin C methods. New sets of patient samples were used for each comparison between 2006 and 2010 (Table 1) .
Plasma cystatin C was analyzed on an Architect ci8200 analyzer (Abbott Diagnostics) with reagents and calibrator from Gentian and on a BN ProSpec analyzer (Siemens Healthcare Diagnostics) with reagents and calibrator from Siemens.
A Deming regression analysis showed no significant difference between the 2 methods in 2006 (Table 1) ; however, both the y intercept and the slope differed significantly from 2007 onward. In 2005, the Gentian (x) and Siemens (y) methods showed strong agreement (y ϭ 1.0507x ϩ 0.0369 mg/L; r 2 ϭ 0.994; n ϭ 95). In March 2006, the 2 methods also gave comparable results (y ϭ 1.005x Ϫ 0.026 mg/L; r 2 ϭ 0.995; n ϭ 92). In December 2007, the slope of the linear regression analysis had decreased by approximately 7% while maintaining a high r 2 value (y ϭ Letters to the Editor
